Loading company
GT Biopharma, Inc.
GTBP · Nasdaq · ·
$6.80-1.7%Sep 29 close
- 1M
- -9.3%
- 6M
- -34.4%
- 1Y
- -53.6%
- 5Y
- -99.9%
GTBP · Nasdaq · ·
$6.80-1.7%Sep 29 close
The quarter ending September 30, 2021, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2021 | 3 months toSep 30, 2020 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$4.5M | -$30.2M | +85.02% |
| Profit per share | -$0.12 | -$10.92 | +98.90% |
| Free Cash Flow | -$485K | -$1.3M | +61.99% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
GT Biopharma, Inc. has no earnings call transcript available.
“We are highly encouraged by the continued progress of our Phase 1 clinical trial evaluating GTB-3650 in cancer patients, which has now advanced to Cohort 4 at a dose level of 10 µg/kg/day ,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based on our proprietary TriKE ® NK cell engager platform. Our TriKE ® platform is designed to harness and enhance the cancer killing abilities of a patient’s immune system’s natural killer cells. GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE ® technology.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from GT Biopharma, Inc.’s Item 2.02 8-K filed November 14, 2025; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.